This document is a pitch deck for AllRest Technologies, which designs and markets medical devices for sleep disorders. It seeks $1.5 million to complete development and market its Opti-Flow device, an alternative to CPAP machines that is more affordable and comfortable. Opti-Flow uses smart sensors and electronics to monitor performance and customize treatment at a lower price point than other solutions. AllRest aims to capture 1.1 million users in the US $53 billion sleep disorder market within 3 years, achieving over 78% EBITDA margins. It provides an overview of the sleep disorder problem, Opti-Flow solution, management team, marketing strategy, revenue model, and barriers to entry.

1. ALLREST TECHNOLOGIES LLC
Pitchdeck Presentation:
Juan Ramon Zarco,
President/COO
juan@allresttech.com
(703) 376-4893

2. 2
HIGHLY CONFIDENTIAL AND PRIVILEGED INFORMATION
The information contained herein is being furnished on a confidential basis. AllRest Technologies LLC (the “Company”) expects it to be used for the sole purpose of considering an interest in a
transaction with the Company. BY RECEIPT OF THE ENCLOSED MATERIALS, THE RECIPIENT AGREES THAT THE INFORMATION CONTAINED HEREIN WILL BE KEPT
CONFIDENTIAL AND SHALL NOT, WITHOUT PRIOR WRITTEN CONSENT FROM THE COMPANY BE DISCLOSED BY THE RECIPIENT IN ANY MANNER WHATSOEVER IN
WHOLE OR IN PART, AND SHALL NOT BE USED OTHER THAN IN CONNECTION WITH THE TRANSACTION DESCRIBED HEREIN. The recipient shall be responsible for any
breach of this confidentiality undertaking by its agents, employees, or representatives. Moreover, the recipient shall agree to transmit the information only to its agents, employees, and
representatives who need to know the information for the purpose of evaluating the materials herein, who are informed of the confidential nature of the information and who agree to maintain its
confidentiality. Should the recipient decline to acquire an interest in any transaction with the Company, it shall return all supplied materials as soon as possible and, in any event, upon request,
and continue to maintain in confidence any memoranda or similar materials prepared by or for the benefit of the recipient based upon the materials supplied to it.
THE ENCLOSED MATERIALS SHALL NOT BE PHOTOCOPIED, REPRODUCED, OR DISTRIBUTED TO OTHERS AT ANY TIME WITHOUT PRIOR WRITTEN
CONSENT OF THE COMPANY.
Contact:
Rob de Heer or Juan Ramon Zarco
(408) 316-1976 (703) 376-4893
AllRest Technologies LLC
PO Box 60123
Palo Alto, CA 94306
(408) 316-1976

3. OVERVIEW
• AlllRest designs and markets cost effective, smart,
therapeutic medical devices for sleep disorders
• U.S. Total Addressable Market (TAM) is 53 million users
• Current working prototype has been developed
since 2009 and has been effective in private trials
• New electronic technologies will allow CRM
monitoring of the medical device’s performance
and adjust the device for maximum efficiency
• EBITDA Margins exceed 78% in this space
• AllRest seeks $1.5 million to complete electronics, to
handle regulatory matters, and to market the device
in the U.S. and Worldwide
AllrestTech.com Private & Confidential 2014
3

4. THE PROBLEM
• The predominant therapy is the
Continuous Positive Air Pressure
(CPAP), the current legacy device
in treating sleep-disordered
breathing.
• 17% - 40% of CPAP patients
abandon the device after several
months – discomfort, costs
• CPAP equipment costs $500-
$5,000
• Other sleep disorder solutions
include surgery, dentally
prescribed mouthpieces-$1,500,
and electrical implants – all
physically invasive and costly
• Over 53 million people suffer from
some sleep disorder. 20% are
untreated. And about 10% are
uninsured.
AllrestTech.com Private & Confidential 2014
4

5. SOLUTION – OPTI-FLOW
• TheAllRest medical device, Opti-
Flow, an alternative to CPAP, is an
advanced technology to be used
easily with the least amount of
sleep discomfort
• Filters can be replaced to fit the
individual’s apnea needs and
performance
• Sensors and data can provide
weekly sleep reports for CRM
• By integrating the medical device
with a health platform, the user
can monitor his/her weight or any
other conditions for better sleep
regimen
• Priced at or below $200, the
device is economically available
to those with or without insurance
coverage
• It improves the Sleep Apnea Index
by 40% at a fraction of a CPAP
AllrestTech.com Private & Confidential 2014
5

6. MARKET OPPORTUNITY AND DRIVERS
 Current U.S. TAM is 53 million users
 Rest Of the World is still catching up to Sleep Disorder recognition and
treatment
 It is estimated that less than 20% of those with Obstructive Sleep Apnea
have not been diagnosed or treated, about 10 million. Over 8 million
apnea sufferers without medical coverage
 According to a report by the global research firm MarketsandMarkets,
the global sleep apnea device market, which was valued at more than
$7 billion last year, is expected to increase to $19.72 billion by 2017
 Potential worldwide growth: A recent report from July 2013 showed that
the US passed on the obesity rates leadership to Mexico, moving into
second place for the most obese nation. Researchers estimate that
Brazil will trail the US in 2022, with 64 million overweight and 26 million
obese.
 According to the report, nearly 2.8 million people worldwide die each
year as a result of obesity and the conditions it causes, which includes
the potential for sleep apnea
 Worldwide TAM will be about 400 million
AllrestTech.com Private & Confidential 2014
6

7. MARKETING STRATEGY
 AllRest will target sales of 1.1 million units in 3 years, within the U.S.
53 million TAM with a growing OSA market
 The Opti-Flow medical device will be priced at or about $200, less
than 50% of the least cost CPAP
 AllRest will implement the “shock and awe” marketing to use
eCommerce and the 1-800-AllRest support to the product
 AllRest will distribute the medical device in Europe and Latin
America where the regulatory hurdles are fewer, and then
penetrate the U.S.
 AllRest will use digital ad agencies to market the product in the
media to saturate the market
AllrestTech.com Private & Confidential 2014
7

8. POTENTIAL CHANNELS/PARTNERS/RESELLERS
 mHealthAlert, a European mHealth platform, already uses
Bluetooth to connect ECG, weight scales, blood pressure,
and other remote devices to monitor health electronically
 CPAP machine manufacturers and distributors (ProAct)
 oral appliance manufacturers
 sleep product stores
 sleep labs.
AllrestTech.com Private & Confidential 2014
8

9. BARRIERS TO ENTRY
FDA approval process
Provisional patent
Integration and design of semiconductors
Market recognition – within radar
Current users wed to CPAP solutions.
AllrestTech.com Private & Confidential 2014
9

10. MANAGEMENT TEAM
 Juan Ramon Zarco, JD/MBA (startups: Viatel, Data
Foundation/Pegasus, US Cable)
 Robert de Heer (inventor, technology, software)
 Dr. Jerome Hester, Chief Advisor and Industry Apnea
Expert (www.calsleep.com)
 Marc Papageorge, Mems/Semiconductor Advisor
 Hogan Lovells (D.C.) – IP Legal Counsel
 Bank of the West
AllrestTech.com Private & Confidential 2014
10

11. AllrestTech.com Private & Confidential 2014
11
DIRECT AND INDIRECT COMPETITION
AllRest (mouth)
Fisher & Paykel
Respiratory
Therapy
Programs
CareFusion
Compatibility
Scalability
Resmed
Respironics
Medtronics
• Resmed and
Respironics
control over
70% of CPAP
Market
• Resmed 2013
Income $1.5
bill.
• Respironics
(Philips) 2013
Income $1.05
bill.
Clinics/Sleep lab
Provent (Nasal)

12. AllrestTech.com Private & Confidential 2014
12

13. REVENUE MODEL
AllrestTech.com Private & Confidential 2014
13
2014 2015 2016 2017 2018
Revenue $0.0 $3,575.8 $219,317.5 $348,750.0 $426,600.0
COGS 0.0 856.5 37,272.1 42,140.0 51,891.0
Total Operating Expenses 423.9 3,576.0 23,626.6 35,678.3 42,664.8
EBITDA (377.2) (856.8) 158,418.8 270,931.7 332,044.2
($50,000.0)
$0.0
$50,000.0
$100,000.0
$150,000.0
$200,000.0
$250,000.0
$300,000.0
$350,000.0
$400,000.0
$450,000.0
Dollars('000s)
AllRest Technologies LLC
ProForma

14. AllrestTech.com Private & Confidential 2014
14
Mouthpiece Prototypes Design Phases and Costs
Prototype Versions 1
Each Prototype Locations
OptiFlow01 USA
OptiFlow02
UK/Mexico/New
Zealand
Developmental Stages per Month/2014 Initial
September Design
October
Development &
Engineering
November
Development &
Engineering
December Programming
January Prototype
February
Reliability &
Testing
March Beta Testing
April Integration
May
Testing and
Regulatory
Acceptance
June
Commercial
Product
TIMELINE

15. SUMMARY
 AllRest enters into a huge Market opportunity with
EBITDA margins over 78%, 1.1 million units in 2 years
 Unique medical device product embedded with
smart electronics, an alternative to CPAPs
 Barriers to entry – FDA approvals, Patents
 Seeking $1.5 mill. at pre-money of $4.5 mill.
 Potential exits are acquisition or IPO
AllrestTech.com Private & Confidential 2014
15

16. ALLREST TECHNOLOGIES LLC
Juan Ramon Zarco,
President/COO
juan@allresttech.com
(703) 376-4893
Thank you!